Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down After Analyst Downgrade

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares gapped down before the market opened on Thursday after Chardan Capital lowered their price target on the stock from $16.00 to $14.00. The stock had previously closed at $4.09, but opened at $3.51. Chardan Capital currently has a buy rating on the stock. Iovance Biotherapeutics shares last traded at $3.6430, with a volume of 14,841,725 shares trading hands.

A number of other analysts have also recently issued reports on the company. Wall Street Zen raised Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. The Goldman Sachs Group reissued a “sell” rating and set a $2.00 price objective on shares of Iovance Biotherapeutics in a research report on Thursday, February 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research report on Monday, April 6th. Truist Financial raised Iovance Biotherapeutics to a “hold” rating in a research report on Wednesday, March 25th. Finally, UBS Group lifted their price objective on Iovance Biotherapeutics from $2.00 to $4.00 and gave the company a “neutral” rating in a research report on Thursday, March 5th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $8.63.

Iovance Biotherapeutics News Summary

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reaffirmed or raised confidence in its longer-term growth story by outlining 2026 revenue guidance of $350 million to $370 million and Q2 revenue guidance of $86 million to $88 million, which suggests management still expects solid commercial momentum. Article: Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
• Positive Sentiment: A Chardan Capital analyst kept a Buy rating on Iovance even after trimming the price target to $14 from $16, indicating Wall Street still sees substantial upside from current levels. Article: Iovance Biotherapeutics had its price target lowered by Chardan Capital
• Neutral Sentiment: The company’s Q1 loss of $0.19 per share matched expectations, and revenue grew 44.9% year over year, showing progress even though the quarter was not enough to satisfy investors. Article: Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates
• Negative Sentiment: Revenue came in below analyst forecasts at $71.43 million versus $77.84 million expected, with weaker-than-expected product sales weighing on sentiment and triggering the stock’s decline. Article: IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Institutional Trading of Iovance Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in IOVA. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Iovance Biotherapeutics during the 3rd quarter worth about $27,000. Arcataur Capital Management LLC bought a new position in Iovance Biotherapeutics during the fourth quarter valued at about $29,000. Granite Investment Partners LLC bought a new stake in shares of Iovance Biotherapeutics in the 4th quarter valued at approximately $29,000. Motley Fool Asset Management LLC bought a new stake in shares of Iovance Biotherapeutics in the 4th quarter valued at approximately $29,000. Finally, M&T Bank Corp bought a new stake in shares of Iovance Biotherapeutics in the 4th quarter valued at approximately $31,000. Institutional investors and hedge funds own 77.03% of the company’s stock.

Iovance Biotherapeutics Stock Performance

The company has a market capitalization of $1.62 billion, a P/E ratio of -3.81 and a beta of 0.69. The firm has a 50 day moving average price of $3.81 and a two-hundred day moving average price of $2.94.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). Iovance Biotherapeutics had a negative return on equity of 50.57% and a negative net margin of 123.92%.The company had revenue of $71.43 million for the quarter, compared to analyst estimates of $77.84 million. During the same period in the prior year, the company posted ($0.36) EPS. The company’s revenue was up 44.9% compared to the same quarter last year. On average, equities analysts expect that Iovance Biotherapeutics, Inc. will post -0.61 earnings per share for the current year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical?stage biotechnology company specializing in the development and commercialization of tumor?infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN?144), is an autologous TIL therapy in late?stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next?generation TIL programs such as LN?145 for cervical and other human papillomavirus (HPV)?related cancers, as well as exploratory studies in head and neck, non?small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor?reactive lymphocytes.